Jens Holstein

Jens Holstein has served on Veracyte’s board of directors since August 2020. Mr. Holstein has over 25 years of financial and management expertise, spanning an array of global life science businesses. He currently serves as Chief Financial Officer of BioNTech SE, an immunotherapy biopharmaceutical company based in Mainz, Germany. Previously, Mr. Holstein was the Chief Financial Officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany, from 2011 to 2020. Before joining MorphoSys, he worked at the pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as Regional Chief Financial Officer for the Europe/Middle East Region and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Previous to this appointment, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry. He has previously served as a director of InflaRx N.V., a biopharmaceutical company. He holds a Diploma in Business Administration from the University of Münster (Germany).